-
Celldex Therapeutics reported third quarter 2026 results with a net loss of US$75.56 million and basic loss per share of US$0.96, alongside a universal shelf registration covering common and preferred stock, warrants, depositary shares and units.
-
The combination of widening losses and a fresh universal shelf registration highlights the pressure on Celldex Therapeutics to secure funding while it continues to invest heavily in its antibody pipeline without meaningful current revenue.
-
We will now look at how Celldex Therapeutics' widening losses and new shelf registration could influence the broader investment narrative.
Scan beyond Celldex Therapeutics and compare how other high risk, early stage plays stack up on balance sheet strength and funding runway using our hand picked 32 resilient stocks with low risk scores
Celldex Therapeutics Investment Narrative Recap
To own Celldex Therapeutics, you need to be comfortable with a loss making biotech that is still essentially pre commercial and heavily tied to barzolvolimab and the broader mast cell program. The latest quarter kept that story intact. Revenue stayed minimal and the business reported a net loss of US$75.56 million, so...